DexCom (DXCM, Financials) shares surged more than 15% on Friday after the company beat first-quarter revenue expectations and unveiled a new $750 million stock buyback plan.Adjusted earnings per share came in at $0.32, narrowly missing expectations by $0.01. Warning! GuruFocus has detected 3 Warning Signs with DXCM. The company reaffirmed its full-year revenue guidance of $4.6 billion and maintained its adjusted operating margin forecast at approximately 21%. The adjusted EBITDA margin outlook also remains around 30%. However, DexCom revised its 2025 adjusted gross profit margin forecast downward to approximately 62%, citing short-term supply-related cost pressures. DexCom, headquartered in San Diego, California, develops continuous glucose monitoring systems for diabetes patients. The new buyback plan reflects confidence in its long-term performance despite near-term margin pressure.Friday's double-digit stock move marked the strongest performance in the S&P 500 and pushed DexCom back into positive territory for 2025. The firm's ability to meet top-line expectations while preserving full-year guidance suggests resilience amid cost headwinds.Investors will be watching how supply-chain costs evolve in the second half of the year and whether the buyback provides further support to shares. See insider trades for DXCM: Explore Peter Lynch chart: View valuation metrics. This article first appeared on GuruFocus. View Comments
DexCom (DXCM) Jumps 15% After Q1 Revenue Beat, $750M Buyback
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...